GlassScriptPhysician profile
Douglas P Williams
NPI 1609872332
$4,364.48
in general payments reported to CMS, 2019-2025
28 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $212 · 2021: $418 · 2022: $564 · 2023: $929 · 2024: $978 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,201.25 | 2019-2025 | Tecnis Simplicity, Veritas Vision System, Tecnis Iol |
| Alcon Vision LLC | $716.97 | 2019-2025 | Rocklatan, Eysuvis, Tryptyr |
| Harrow Eye, LLC | $430.33 | 2023-2025 | Vevye, Iheezo |
| Rxsight INC | $394.13 | 2022-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Sun Pharmaceutical Industries INC. | $271.78 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $224.79 | 2022-2025 | Envista Mx60 Iol, Vyzulta, Miebo |
| Kala Pharmaceuticals, INC. | $223.46 | 2019-2021 | |
| Abbvie INC. | $208.01 | 2022-2025 | Lumigan, Durysta, Alphagan P |
| Dompe US, INC. | $112.78 | 2024-2025 | Oxervate |
| Allergan, INC. | $60.13 | 2019-2021 | |
| Beaver-Visitec International, INC. | $53.46 | 2023 | |
| Mallinckrodt Hospital Products INC. | $53.10 | 2023-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $51.21 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $44.06 | 2023-2024 | Iyuzeh |
| Ocular Therapeutix, INC. | $43.04 | 2019-2024 | Dextenza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $38.14 | 2021-2022 | |
| Eyepoint US, INC. | $36.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.54 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $24.87 | 2023 | Purified Cortrophin Gel |
| Amgen INC. | $21.15 | 2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $19.40 | 2021 | |
| Omeros Corporation | $17.44 | 2019 | |
| Biotissue Holdings INC. | $17.04 | 2025 | |
| Shire North American Group INC | $16.67 | 2019 | |
| Aerie Pharmaceuticals, INC. | $15.86 | 2020 | |
| Horizon Therapeutics Plc | $14.19 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.50 | 2020 | |
| Glaukos Corporation | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.